Welcome to our dedicated page for National Health Investors SEC filings (Ticker: NHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for National Health Investors, Inc. (NYSE: NHI) provides direct access to the company’s official regulatory disclosures as a self-managed real estate investment trust focused on senior housing and medical facility investments. Incorporated in 1991, NHI files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that together outline its financial condition, portfolio activity, capital structure, and risk factors.
For this senior housing and medical facility REIT, 10-K and 10-Q filings are key resources for understanding segment performance in the Real Estate Investments and Senior Housing Operating Portfolio (SHOP) segments, including rental income, interest income from mortgage and other notes receivable, and resident fees and services. These reports also reference risk considerations such as tenant concentration, regulatory exposure to Medicare and Medicaid, real estate illiquidity, access to capital, and the need to maintain REIT status.
Form 8-K filings for NHI frequently cover material events such as public offerings of senior notes, changes in board composition, investor presentations, supplemental information releases, earnings announcements, and certain tenant or lease matters. Examples include 8-Ks describing the completion of a senior notes offering governed by an indenture with restrictive covenants, notices of non-compliance and default under a master lease with a tenant, and change in control severance agreements with named executive officers.
Through this page, users can follow debt and capital markets activity, including details of senior note issuances and related indentures, as well as governance and compensation disclosures reported under Items 1.01, 2.02, 5.02, 7.01, and 8.01 of Form 8-K. Stock Titan’s tools layer AI-powered summaries on top of these filings, helping explain complex topics such as FFO reconciliations, lease structures, credit facilities, and covenant frameworks in accessible language while preserving the underlying SEC source documents for detailed review.
National Health Investors reports 2025 operating and strategic progress while publishing its Annual Report on Form 10-K. Net income per diluted share declined 3.5% versus 2024, but underlying operating measures improved: NFFO per share rose 10.6% and FAD rose 13.7%. Total revenues were $375.6 million, up 12.1%.
SHOP expansion drove results: SHOP NOI rose ~57% with 7.6% same-store growth as SHOP grew from 15 to 26 properties and now represents ~$740 million of investment. Management highlights a strong pipeline (~$488 million), leverage below 4.0x net debt to adjusted EBITDA, substantial liquidity, and continued board refreshment and governance updates.
National Health Investors, Inc. is asking stockholders to elect seven directors, approve executive pay on an advisory basis, and ratify BDO USA as auditor at its May 27, 2026 hybrid annual meeting. The proxy highlights 2025 results, with Normalized FFO per share up 10.6% to $4.91 and Normalized FAD up 13.7% to $232.1 million, both above initial guidance. Nareit FFO per share rose 2.2% to $4.65, while 2025 TSR increased 15.7%, with three‑ and five‑year TSR of 72.9% and 47.7%. The company completed $392.4 million of investments at an average 8.08% yield and grew SHOP NOI 57.2% to $19.1 million, as net debt to adjusted EBITDA improved to 3.8x. Governance changes include declassifying the board, expanding to nine directors then reducing to seven nominees, raising female representation to 43%, updating key governance documents, and enhancing pay‑for‑performance through capped annual incentives and a more performance‑weighted long‑term equity program.
NATIONAL HEALTH INVESTORS INC updated an insider ownership report for SVP, Legal Affairs Elizabeth Jackson Blankenship to reflect a previously omitted stock option grant. The amendment shows three tranches of stock options, each with an exercise price of $73.34 per share and expiring on March 3, 2030.
The options relate to underlying Common Stock in amounts of 8,333, 8,333 and 8,334 shares, with exercisability dates on March 3, 2025, March 3, 2026 and March 3, 2027, respectively. The footnote explains the grant was inadvertently omitted from the original Form 3 and is held directly.
PASCOE KEVIN CARLTON reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors Inc. reported that Chief Investment Officer Kevin Carlton Pascoe received a grant of 4,726 shares of common stock on March 3, 2026, at no cash cost to him. After this compensation-related award, he directly holds 73,082 common shares.
The filing is an amended Form 4 that corrects an earlier administrative error, which had overstated the number of shares awarded on that date by 346 shares. This amendment updates the record to show the accurate number of shares granted.
Spaid John L reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors Inc. reported that CFO and EVP Finance John L. Spaid received a corrected equity award of 5,072 shares of Common Stock on March 3, 2026, recorded at $0.00 per share as a compensation grant. An earlier report understated this award by 346 shares, and this amended Form 4 updates the figure. Following the grant, Spaid directly owns 56,600.637 shares of National Health Investors common stock.
National Health Investors Inc Schedule 13G/A amendment shows The Vanguard Group reports zero beneficial ownership of the company's common stock following an internal realignment. The filing states Vanguard and certain subsidiaries will report holdings separately and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries.
National Health Investors, Inc. established a new equity distribution program allowing it to sell up to $500,000,000 of common stock from time to time. Sales may be made through multiple banks acting as sales agents, principals, and forward sellers under a Form S-3 shelf registration.
The company can also enter into forward sale agreements under which banks borrow and sell shares now, with National Health Investors delivering shares or cash at later settlement dates. The company does not receive cash from forward sellers’ initial sales, but expects to receive proceeds when it physically settles forward contracts.
Net proceeds from direct sales and any forward settlements are expected to be used for general corporate purposes, including potential future acquisitions and repayment of indebtedness such as borrowings under its credit facilities. Sales agents and forward sellers may receive commissions of up to 1.50% of the gross sales price of shares sold through them.
National Health Investors, Inc. is offering up to $500,000,000 of its common stock through an equity distribution agreement (an at-the-market program) with multiple broker-dealers.
The shares may be sold from time to time at prevailing market prices through the Sales Agents or through Forward Sellers under forward sale agreements; we may physically, cash or net share settle forward sales. Shares outstanding were 48,459,206 as of March 12, 2026.
Donohue Lilly reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors director Lilly Donohue reported receiving a grant of 1,268 shares of common stock as restricted stock.
The award was granted on March 3, 2026 and will vest in full on March 3, 2027, as long as she continues serving as a director through that date. Following this grant, her directly owned stake is 1,268 shares.
COLDEN TRACY M J reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors director receives stock grant. Director Tracy M. J. Colden was awarded 1,268 shares of National Health Investors common stock on March 3, 2026 as restricted stock. These shares vest in full on March 3, 2027, subject to continued board service, bringing her direct holdings to 12,858 shares.